HIV-1 drug resistance among naïve patients in Armenia in 2017–2021

Full Text

Introduction

The Republic of Armenia is a country in Eastern Europe and Central Asia (EECA) that has been actively engaged in the fight against HIV/AIDS over the past decades. According to the United Nations Global Statistics on HIV/AIDS (UNAIDS), there were 1.8 million people living with HIV in EECA as of 2021, and the number of new infections continues to increase¹.

After the collapse of the Soviet Union, a period of economic collapse severely weakened the health infrastructure of the newly independent republics. At that time, little attention was paid to the HIV-1 epidemic. Much of the former Soviet Union was experiencing one of the fastest growing HIV-1 epidemics in the world, with the number of infected individuals doubling annually in certain regions [1]. Open border policies in the regions did not prevent migration, which in turn facilitated the spread of infectious diseases². Research results show that among Armenian citizens the highest HIV-1 prevalence was recorded among migrant workers [2, 3].

One of the main reasons for the increase in HIV-1 infections in Armenia was the low level of access to antiretroviral therapy (ART). However, in low- and middle-income countries, ART was introduced only in the mid-2000s [4]. Thanks to the efforts of the World Health Organization (WHO) in the early twenty first century, the inequality between rich and poor countries in terms of treatment options decreased. Developing countries were able to purchase drugs at affordable prices, which in turn reduced mortality. During this period, the first guidelines for HIV-1 treatment in resource-limited settings were published, which contained simplified treatment regimens [5].

At present, the incidence of HIV infection in Armenia is low. The total number of infected cases does not exceed 4,600 people, which is only 0.12% of the country's population³. Much like in other countries, programs in Armenia are aimed at achieving the goals of UNAIDS. As a result of the "90-90-90" strategy, a good result was achieved in the region — in 2020, 81% of people living with HIV knew their status and 86% of people who were prescribed ART achieved an undetectable viral load⁴. As of 2018, the preferred treatment regimen includes the integrase inhibitor (INI) dolutegravir in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) — tenofovir, lamivudine or emtricitabine. An alternative regimen is two NRTIs (tenofovir and lamivudine) and one non-nucleoside reverse transcriptase inhibitor (NNRTI) drug, efavirenz⁵.

Due to the increasing number of patients on ART, the development of viral resistance is a significant challenge in combating the HIV epidemic. WHO recommends drug resistance testing prior to treatment initiation and when ART is ineffective. Unfortunately, this approach is not available to all countries. In most developing countries, only certain groups of patients are tested and only in cases of virological failure of ART⁶.

HIV resistance testing is also recommended for epidemiologic surveillance of drug resistance (DR) [6]. According to WHO reports, the prevalence of transmitted DR for 2017 and 2020 has exceeded the 5% threshold in most countries, with 67% of countries exceeding 10%. The presence of HIV-1 DR in naive patients reduces the selection of effective ART and may increase the risk of virologic treatment failure [7].

Previously published studies have investigated the prevalence of HIV-1 DR in Armenia in untreated patients and reported a significant increase in resistance. While in 2015 the resistance rate was only 1.5%, in the 2020 and 2021 studies, the prevalence of DR increased to 5.5% and 9.2%, respectively, and approached the WHO 10% threshold, upon reaching which clinical treatment guidelines should be revised [8–10]. However, the 2022 publication indicated a decrease in DR in naive patients to 7.5% in 2020–2021 [11]. Previous studies of HIV-1 DR were characterized by small sample sizes and therefore had limited reliability of results.

The aim of the scientific research is to assess the prevalence and pattern of HIV-1 drug resistance in the Republic of Armenia by analyzing a large cohort of patients with no history of taking antiretroviral drugs.

Materials and methods

The collection of biological material and related patient information took place in 2018–2022. A total of 982 patients who had not previously received ART participated in the study. Patients were included consecutively during routine visits to the Republican AIDS Prevention Center of the Ministry of Health of the Republic of Armenia. Demographic and clinical data collected included age, sex, date of first positive immune blot, presumed HIV-1 transmission route, HIV-1 RNA viral load and CD4+ cell count.

Samples were analyzed by mass parallel sequencing using a laboratory technique developed at the Central Research Institute of Epidemiology (n = 367) or by classical Sanger sequencing using the AmpliSense HIV-Resist-Seq reagent kit (Central Research Institute of Epidemiology) (n = 615). If mass parallel sequencing was used, three viral genes were analyzed: protease, reverse transcriptase and integrase. If Sanger sequencing was used, the nucleotide sequences of the protease gene and a fragment of the reverse transcriptase gene, in which resistance mutations may appear, were obtained. Sequencing was performed using MiSeq (Illumina) and Applied Biosystems 3500 Genetic Analyzer (Life Technologies) instruments.

Preliminary HIV-1 subtyping was performed using the online tools REGA v. 3.0⁷ and Stanford University database⁸. The results of preliminary subtyping were verified by phylogenetic analysis using the MEGA v. 6.0 software with reference sequences of HIV-1 subtypes and recombinant forms downloaded from the Los-Alamos database⁹. Nucleotide sequence alignment and further editing were performed using BioEdit v. 7.2¹⁰.

The quality of nucleotide sequences was assessed using the WHO HIV DR v. 2.30¹¹ and Calibrated Population Resistance Tool¹².

DR to antiretroviral drugs were identified using the Stanford University database. Surveillance drug resistance mutations (SDRM) were identified using WHO Surveillance Drug Resistance Mutation Worksheet 2014.

The study was conducted with the informed consent of the patients. The study was approved by the local ethical committee of the Central Research Institute of Epidemiology of Rospotrebnadzor (Moscow, Russia) on May 21, 2019 (protocol No. 92).

RESULTS

Characteristics of the study group

The mean age of participants at the time of inclusion in the study was 41 (19-75) years, with the largest number of people with HIV infection being aged 30-40 years; 68.9% of patients were male. Heterosexual transmission was predominant (83.2%) as the most likely route of transmission in the study group.

Subtyping results showed a high degree of genetic diversity among the variants circulating in the study region. HIV-1 sub-subtype A6 was predominant with a prevalence of 87.0%, with subtype B being the next most frequent (5.9%). Subtypes A1, C and G were also detected in isolated cases. In addition, 6 different recombinant forms were detected –CRF02_AG, CRF03_A6B, CRF06_cpx, CRF20_BG, CRF24_BG and CRF63_02A6, which are frequently found in EECA countries.

The epidemiologic data of the study participants are presented in Table 1. A 95% confidence interval (CI) was calculated for each epidemiologic group.

 

Table 1. Epidemiological characteristics of patients included in the study, n (%; 95% CI)

Characteristics	Men	Women	All
Number of patients	677 (68.9; 66.0–71.8)	305 (31.1; 28.2–34.0)	982
Transmission risk group of infection
Heterosexual	514 (52.3; 49.2–55.5)	303 (30.9; 28.0–33.8)	817 (83.2; 80.7–85.4)
Men who have sex with men	98 (10.0; 8.3–12.0)	–	98 (10.0; 8.3–12.0)
Injecting drug users	65 (6.6; 5.2–8.4)	2 (0.2; < 0.01–0.8)	67 (6.8; 5.4–8.6)
HIV-1 genetic variants
A1	1 (0.1; < 0.01–0.6)	0	1 (0.1; < 0.01–0.6)
A6	567 (57.7; 54.6–60.8)	287 (29.2;26.5–32.2)	854 (87.0; 84.7–88.9)
B	56 (5.7; 4.4–7.3)	2 (0.2; < 0.01–0.8)	58 (5.9; 4.6–7.6)
C	1 (0.1; < 0.01–0.6)	1 (0.1; < 0.01–0.6)	2 (0.2; < 0.01–0.8)
G	1 (0.1; < 0.01–0.6)	0	1 (0.1; < 0.01–0.6)
CRF02_AG	16 (1.6; 1.0–2.7)	6 (0.6; 0.3–1.4)	22 (2.2; 1.5–3.4)
CRF03_A6B	5 (0.5; 0.2–1.2)	2 (0.2; < 0.01–0.8)	7 (0.7; 0.3–1.5)
CRF06_cpx	2 (0.2; < 0.01–0.8)	1 (0.1; < 0.01–0.6)	3 (0.3; 0.1–0.9)
CRF20_BG	1 (0.1; < 0.01–0.6)	0	1 (0.1; < 0.01–0.6)
CRF24_BG	7 (0.7; 0.3–1.5)	0	7 (0.7; 0.3–1.5)
CRF63_02A6	20 (2.0; 1.3–3.1)	6 (0.6; 0.3–1.4)	26 (2.7; 1.8–3.9)

 

Assessment of prevalence of DR to antiretroviral drugs and resistance mutations

We analyzed 982 nucleotide sequences for HIV-1 DR to NNRTI, NRTI, and PI class antiretroviral drugs and 367 nucleotide sequences for HIV-1 DR to PI class drugs.

The overall prevalence of HIV DR to all drug classes was 13.8% (95% CI 11.8–16.2%). DR to individual antiretroviral drug classes occurred at a frequency of 2.0% (95% CI 1.3–3.1%) to PIs, 1.4% (95% CI 0.8–2.4%) to NRTIs, 11.2% (95% CI 9.4–13.3%) to NNRTIs, and 0.5% (95% CI 0.02–2.1%) to INIs. Details of the prevalence of DR to each drug separately are presented in Figure 1.

 

Fig. 1. Frequency of occurrence and level of resistance to antiretroviral drugs.

 

HIV DR was most frequently registered for the drug rilpivirine of the NNRTI class — in 9.7% of cases, but in 7.6% of cases it was low-level resistance. To other drugs of this class, nevirapine and efavirenz, DR was detected in 4.2 and 3.5% of cases, respectively, and it was mostly high-level resistance. Resistance to antiretroviral drugs of NRTI, PI and INI classes individually did not exceed 2%.

HIV-1 surveillance drug resistance mutations (SDRM) detected in more than one patient are presented in Table 2.

 

Table 2. Surveillance HIV-1 drug resistance mutations HIV-1 identified more than in one patient

Surveillance DR mutations	Patients count	Prevalence mutations, % (95% CI)
Mutations NNRTI
K101E	13	1.3 (0.8–2.3)
K103N	12	1.2 (0.7–2.2)
Y181C	7	0.7 (0.3–1.5)
G190A	8	0.8 (0.4–1.6)
Mutations NRTI
T69D	3	0.3 (0.06–0.9)
M184V	4	0.4 (0.1–1.1)
L210W	5	0.5 (0.2–1.2)
T215D	4	0.4 (0.1–1.1)
Mutations PI
D30N	2	0.2 (< 0.001–0.8)
M46I	6	0.6 (0.2–1.4)

 

Surveillance mutations associated with DR to PI class antiretroviral drugs were detected in only two cases — in one patient E92G and in the second patient Y143H.

The overall prevalence of HIV-1 surveillance DR mutations was 1.4% (95% CI 0.8–2.4%) to PI class antiretroviral drugs, 1.5% (95% CI 0.9–2.5%) to NNRTI class, 3.1% (95% CI 2.1–4.3%) to NNRTI class, and 0.6% (95% CI 0.02–2.1%) to INI class.

Dependence of resistance prevalence on the analyzed indicators of the study sample

In this study, we researched the dynamics of the prevalence of DR to antiretroviral drugs of different classes depending on the year of the first positive immunoblot test. To obtain comparable cohort sizes, groups of patients with detected HIV infection were formed: up to and including 2017 (146 people), in 2018 (241 people), in 2019 (332 people), in 2020 (81 people) and in 2021 (182 people). The results of the analysis are presented in Figure 2. The dynamics of the overall prevalence of HIV-1 DR to antiretroviral drugs was largely driven by DR to NNRTI class antiretroviral drugs. During the study period, a slight upward trend of DR in the country was noted. It should also be noted that since 2020, a significant proportion of patients started to receive dolutegravir in the first-line therapy regimen of antiretroviral drugs from the INI group, and the share of such patients increased from 30% to 80% by the end of 2021 [8, 11]. This is possibly associated with the emergence of isolated cases of virus resistance to antiretroviral drugs of this class in 2019–2020.

The association between the prevalence of HIV-1 DR to antiretroviral drugs and genetic variants of the virus was analyzed. Among variants occurring in more than 1% of cases, subtype B viruses were the most frequently resistant, showing DR in 36.2% of cases (in 21 patients out of 58). DR prevalence above average was also reported in patients infected with CRF63_02A6, 15.4% (in 4 patients out of 26). DR detection rates below average were found in patients with sub-subtype A6, 11.5% (in 98 patients out of 854) and CRF02_AG, 9.1% (in 3 patients out of 22).

The prevalence of HIV-1 DR to antiretroviral drugs was recorded almost one and a half times more frequently in men than in women, 15.4% versus 10.5% (p = 0.041). Analysis of the prevalence of resistance according to the perceived risk group showed that resistant variants were found most frequently among men who have sex with men (27.6%, 27 out of 98), followed by injection drug users (17.9%, 12 out of 67). Drug-resistant viruses were least frequently detected among patients infected during heterosexual contact (11.9%, 97 of 817).

 

Fig. 2. The dynamics of HIV-1 drug resistance by the year of the first positive immune blot.

 

At the final stage, the prevalence of HIV-1 DR to antiretroviral drugs in different regions of Armenia was analyzed. All of them were divided into three groups: Yerevan city; regions adjacent to Yerevan; regions distant from Yerevan. The results are presented in Table 3.

 

Table 3. Prevalence of HIV-1 DR in the regions of Armenia

Region	Patients count	Patients with drug resistance count	Prevalence, %
Yerevan	278	47	16.9
Nearby regions
Aragatsonion	34	4	11.8
Armavir	79	12	15.2
Ararat	94	11	11.7
Kotay	77	9	11.7
Remote regions
Vayodzor	18	1	5.6
Gegharkunik	96	10	10.4
Lori	91	11	12.1
Syunik	68	12	17.6
Tavush	30	6	20.0
Shirak	117	13	11.1

 

In certain regions, such as Syunik and Tavush, the prevalence of HIV-1 DR was the highest. However, on average, the prevalencee rates in nearby and remote regions were lower than in the capital city, being 12.7% and 12.6%, respectively.

Discussion

This study is a national epidemiologic investigation of HIV-1 DR in the Republic of Armenia using a large sample of naive patients. The overall prevalence of DR to antiretroviral drugs was 13.8% and was slightly higher than described in other studies. Research groups that have previously studied HIV resistance in patients with no prior experience of taking ART have shown prevalence ranging from 5.5% to 9.2% [9–11]. However, it should be taken into account that in these studies, DR was not assessed to all antiretroviral drugs. In particular, according to previous studies, resistance to antiretroviral drugs of the NNRTI group ranged from 4.4% to 6.0%; in our study, this indicator increased to 11.2% [9, 11]. This significant difference was obtained due to the fact that the HIV-1 DR to rilpivirine was taken into account in our study. In the previous study [11], the resistance rates to EFV and NVP were 6% and 6.8%, while in the current study they were 3.5% and 4.2%, respectively [9, 11].

Antiretroviral drugs of the NNRTI group have a low genetic barrier, and a single point substitution in reverse transcriptase can lead to the development of high-level resistance and subsequently to the transmission of resistant variants with alterations into the population. Therefore, mutations that significantly reduce sensitivity to nevirapine and efavirenz continued to persist among patients in this class. As primary resistance testing is not routinely performed in the region, and due to the 2018 WHO guidelines, a combination of 2 NRTIs + 1 INI was started in the first-line therapy regimen. Nevirapine was removed from the list of drugs for HIV-1 treatment in Armenia, and efavirenz was recommended for prescription as part of an alternative regimen.

At the same time, a low prevalence of DR was recorded in relation to NRTI, PI and INI classes. The rate of DR to NRTI drugs decreased significantly from 5.0% to 1.4% [10, 11]. The most frequently detected substitutions in patients were those causing high levels of DR to lamivudine and emtricitabine.

In our study, for the first time in the Republic of Armenia, the efficacy of INI class drugs in those who have not undergone ART was evaluated and resistance mutations were identified that significantly reduced sensitivity to raltegravir and partially to elvitegravir.

The results showed that drug combinations used in 1st line therapy are effective, and this is supported by data on the increase in undetectable viral load in individuals receiving ART from 68% in 2016 to 86% in 2020¹³. However, regimens containing efavirenz and nevirapine should be cautiously prescribed or minimized, as the proportion of circulating drug-resistant variants of the virus to each of the drugs is quite high, at approximately 4%¹⁴.

The overall prevalence of mutations important for surveillance did not exceed 5% for any of the antiretroviral drugs classes individually and was highest for the NNRTI class (3.1%).

In our study, associations between the presence of drug resistance and various virus and patient characteristics were analyzed. It was found that the probability of resistance was much higher in case of infection caused by subtype B virus. Drug-resistant variants were registered more often in male patients, from the risk group of men having sexual contacts with men, living in Yerevan city.

The prevalence of HIV-1 variants with high-level resistance increases the risk of primary DR transmission. Therefore, estimation of the prevalence of transmitted DR is an objective necessity not only for successful prescription of therapy, but also for minimizing the risk of transmission of DR variants of the virus.

Conclusion

In our study, the rate of HIV-1 DR to antiretroviral drugs in patients with no history of therapy was 13.8%. However, it was mainly due to resistance to NNRTI class of antiretroviral drugs. These results suggest that the currently recommended antiretroviral drugs of NNRTI, PI and INI classes are likely to be effective, and that viral resistance will have a low negative impact on achievement of the goals of the UNAIDS "95-95-95" strategy in Armenia. The study was carried out on a sample of 982 HIV-infected patients and allowed to assess HIV-1 DR in more than 20% of the country's citizens diagnosed with HIV infection.

 

¹ UNAIDS. Global HIV & AIDS statistics — Fact sheet 2022. URL: https://www.unaids.org/ru/resources/fact-sheet

² UNAIDS. Global HIV & AIDS statistics — Fact sheet 2019. URL: https://www.unaids.org/ru/resources/fact-sheet

³ Joint United Nations Programme on HIV/AIDS 2021. URL: https://www.unaids.org/sites/default/files/media_asset/JC3032_AIDS_Data_book_2021_En.pdf

⁴ UNAIDS DATA, 2021. URL: https://www.unaids.org/en/resources/documents/2021/2021_unaids_data

⁵ Monitoring for procurement of drugs for HIV and HCV treatment; development of solutions to optimize the situation in order to promote uninterrupted access to drugs in the Republic of Armenia, 2020. URL: https://itpc-eeca.org/wp-content/uploads/2020/11/armenia_monitoring_final_05.11.2020.pdf

⁶ World Health Organization‎. Global action plan on HIV drug resistance 2017–2021: 2018 progress report, July 2018: executive summary. URL: https://apps.who.int/iris/handle/10665/273049

⁷ Stanford University. REGA HIV-1 Subtyping Tool — Version 3.0. URL: http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/

⁸ Stanford University. HIV Drug Resistance Database. URL: https://hivdb.stanford.edu/

⁹ HIV databases. URL: https://www.hiv.lanl.gov/content/index

¹⁰ URL: https://bioedit.software.informer.com

¹¹ URL: https://sequenceqc.bccfe.ca/who_qc

¹² URL: https://hivdb.stanford.edu/cpr

¹³ European Centre for Disease Prevention and Control Continuum of HIV care. Monitoring Implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2018 Progress Report. Stockholm: ECDC. 2018. URL: https://www.ecdc.europa.eu/en/publications-data/continuum-hiv-care-monitoring-implementation-dublin-declaration-2018-progress (Accessed: 05.08.2022); European Centre for Disease Prevention and Control Continuum of HIV Care. Monitoring Implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2020 Progress Report. Stockholm: ECDC. 2021. URL: https://www.ecdc.europa.eu/en/publications-data/hiv-continuum-care-monitoring-implementation-dublin-declaration (Accessed: 05.08.2022).

¹⁴ International Treatment Preparedness Coalition Monitoring the Procurement of Drugs for the Treatment of HIV Infection and HCV. Development of Solutions to Optimize the Situation in Order to Promote Uninterrupted Access to Drugs in the Republic of Armenia, 2018–2019. URL: https://itpc-eeca.org/wp-content/uploads/2019/11/Monitoring-zakupok-preparatov-Armeniya_2018-2019.pdf (Accessed: 05.08.2022)

About the authors

Olga A. Osadchaya

Central Research Institute of Epidemiology

Email: osadchaya96@yandex.ru
ORCID iD: 0000-0003-1543-5579

junior researcher, Laboratory of diagnostics and molecular epidemiology of HIV-infection

Россия, Moscow

Dmitry E. Kireev

Central Research Institute of Epidemiology

Email: osadchaya96@yandex.ru
ORCID iD: 0000-0002-7896-2379

Cand. Sci. (Biol.), researcher, Laboratory of diagnostics and molecular epidemiology of HIV-infection

Россия, Moscow

Daria V. Saleeva

Central Research Institute of Epidemiology

Email: osadchaya96@yandex.ru
ORCID iD: 0000-0002-5870-5594

researcher, Laboratory of diagnostics and molecular epidemiology of HIV-infection

Россия, Moscow

Alina A. Kirichenko

Central Research Institute of Epidemiology

Email: osadchaya96@yandex.ru
ORCID iD: 0000-0002-7116-0138

researcher, Laboratory of diagnostics and molecular epidemiology of HIV-infection

Россия, Moscow

Ilya A. Lapovok

Central Research Institute of Epidemiology

Email: osadchaya96@yandex.ru
ORCID iD: 0000-0002-6328-1415

Cand. Sci. (Biol.), senior researcher, Laboratory of diagnostics and molecular epidemiology of HIV-infection

Россия, Moscow

Alexey E. Lopatukhin

Central Research Institute of Epidemiology

Email: osadchaya96@yandex.ru
ORCID iD: 0000-0002-2826-699X

researcher, Laboratory of diagnostics and molecular epidemiology of HIV-infection

Россия, Moscow

Anastasia V. Shlykova

Central Research Institute of Epidemiology

Email: osadchaya96@yandex.ru
ORCID iD: 0000-0002-1390-8021

researcher, Laboratory of diagnostics and molecular epidemiology of HIV-infection

Россия, Moscow

Leila F. Makhmudova

Central Research Institute of Epidemiology

Email: osadchaya96@yandex.ru
ORCID iD: 0009-0002-8168-9497

laboratory assistant researcher, Laboratory of diagnostics and molecular epidemiology of HIV-infection

Россия, Moscow

Natalia N. Ladnaya

Central Research Institute of Epidemiology

Email: osadchaya96@yandex.ru
ORCID iD: 0000-0003-2994-151X

Cand. Sci. (Biol.), senior researcher, Federal Scientific and Methodological Center for the Prevention and Control of AIDS

Россия, Moscow

Ermis M. Hovakimyan

National Center for Infectious Diseases

Email: osadchaya96@yandex.ru

Head, Clinical department

Армения, Yerevan

Siranush V. Martoyan

National Center for Infectious Diseases

Email: osadchaya96@yandex.ru
ORCID iD: 0000-0002-2067-9503

epidemiologist

Армения, Yerevan

Hovsep K. Kazaryan

National Center for Infectious Diseases

Email: osadchaya96@yandex.ru
ORCID iD: 0000-0001-5612-8933

 Cand. Sci. (Biol.), scientific researcher

Армения, Yerevan

Tamara V. Hovsepyan

National Center for Infectious Diseases

Author for correspondence.
Email: osadchaya96@yandex.ru

Head, Diagnostic laboratory

Армения, Yerevan

Narina K. Sargsiants

National Center for Infectious Diseases

Email: osadchaya96@yandex.ru

Cand. Sci. (Med.), deputy director

Армения, Yerevan

Vadim V. Pokrovsky

Central Research Institute of Epidemiology

Email: osadchaya96@yandex.ru
ORCID iD: 0000-0002-9514-7288

D. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Head, Specialized research department for the prevention and control of AIDS

Россия, Moscow

References

Supplementary files